EX-99.d.15
INVESTMENT ADVISORY AGREEMENT
AGREEMENT made this 23rd day of May, 2000 by and between The Xxxxxxx Funds, a
Delaware Business Trust (the "Trust") and Xxxxxxx Partners, Inc., a Delaware
corporation (the "Advisor").
1. Duties of the Advisor. The Trust hereby appoints the Advisor to act as
---------------------
investment advisor to the Global Biotech Fund (the "Series") for the period and
on such terms set forth in this Agreement. The Trust employs the Advisor to
manage the investment and reinvestment of the assets of the Series, to
continuously review, supervise and administer the investment program of the
Series, to determine in its discretion the assets to be held uninvested, to
provide the Trust with records concerning the Advisor's activities which the
Trust is required to maintain, and to render regular reports to the Trust's
officers and Board of Trustees concerning the Advisor's discharge of the
foregoing responsibilities. The Advisor shall discharge the foregoing
responsibilities subject to the control of the officers and the Board of
Trustees of the Trust, and in compliance with the objectives, policies and
limitations set forth in the Trust's Prospectus and Statement of Additional
Information. The Advisor accepts such employment and agrees to render the
services and to provide, at its own expense, the office space, furnishings,
equipment and the personnel required by it to perform the services on the terms
and for the compensation provided herein. With respect to foreign securities,
at its own expense, the Advisor may obtain statistical and other factual
information and advice regarding economic factors and trends from its foreign
subsidiaries, but it may not generally receive advice or recommendations
regarding the purchase or sale of securities from such subsidiaries.
2. Portfolio Transactions. The Advisor shall provide the Series with a
-----------------------
trading department and with respect to foreign securities, the Advisor is
authorized to utilize the trading department of its foreign subsidiaries. The
Advisor shall select, and with respect to its foreign subsidiaries, shall
monitor the selection of, the brokers or dealers that will execute the purchases
and sales of securities for the Series and is directed to use its best efforts
to ensure that the best
available price and most favorable execution of securities transactions for the
Series are obtained. Subject to policies established by the Board of Trustees of
the Trust and communicated to the Advisor, it is understood that the Advisor
will not be deemed to have acted unlawfully, or to have breached a fiduciary
duty to the Trust or in respect of the Series, or be in breach of any obligation
owing to the Trust or in respect of the Series under this Agreement, or
otherwise, solely by reason of its having caused the Series to pay a member of a
securities exchange, a broker or a dealer a commission for effecting a
securities transaction for the Series in excess of the amount of commission
another member of an exchange, broker or dealer would have charged if the
Advisor determines in good faith that the commission paid was reasonable in
relation to the brokerage or research services provided by such member, broker
or dealer, viewed in terms of that particular transaction or the Advisor's
overall responsibilities with respect to the accounts, including the Series, as
to which it exercises investment discretion. The Advisor will promptly
communicate to the officers and directors of the Trust such information relating
to the Series transactions as they may reasonably request.
3. Compensation of the Advisor. For the services to be rendered by the
----------------------------
Advisor as provided in Section 1 and 2 of this Agreement, the Global Biotech
Fund shall pay to the Advisor annual management fees of 1.15%, calculated on the
Series' daily net assets to be paid to the Advisor within five business days
after the end of each month.
In the event of termination of this Agreement, the fee provided in this
Section 3 shall be paid on a pro rata basis, based on the number of days when
this Agreement was in effect.
4. Reimbursement Of Fee Waivers And Expense Reimbursements. If on any day
--------------------------------------------------------
during which this Agreement is in effect, the estimated annualized Operating
Expenses (as defined below) of the Series for that day are less than the
Operating Expense Limit (as defined below), the Advisor shall be entitled to
reimbursement by the Series of the investment management fees waived or reduced,
and of any expense reimbursements or similar payments remitted by the Advisor to
the Series pursuant to the Advisor's agreement to limit the Series' Operating
Expenses (the "Reimbursement Amount") during any of the previous five (5) years,
to
the extent that the Series' annualized Operating Expenses, plus the amount so
reimbursed, equals, for such day, the Operating Expense Limit, provided that
such amount paid to the Advisor will in no event exceed the total Reimbursement
Amount and will not include any amounts previously reimbursed by the Series to
the Advisor. For purposes of this Section 4: (i) "Operating Expenses" shall
include the ordinary operating expenses incurred by the Series in any fiscal
year, including, without limitation, management fees paid to the Advisor, but
excluding interest, taxes, brokerage commissions, other investment-related costs
and extraordinary expenses not incurred in the ordinary course of the Series'
business; and (ii) "Operating Expense Limit" shall mean, with respect to the
Series' Class I shares, 1.30% of average daily net assets of the Series, and
shall mean, with respect to the Series' Class N shares and UBS Investment Fund
shares, 1.30% of the Series' average daily net assets, plus any distribution
service fees under Rule 12b-1 under the Investment Company Act of 1940 and/or
shareholder service fees as described in the then current registration statement
of the Series.
5. Reports. The Series and the Advisor agree to furnish to each other such
--------
information regarding their operations with regard to their affairs as each may
reasonably request.
6. Status of Advisor. The services of the Advisor to the Series are not to
------------------
be deemed exclusive, and the Advisor shall be free to render similar services to
others so long as its services to the Series are not impaired thereby.
7. Liability of Advisor. In the absence of willful misfeasance, bad faith,
---------------------
gross negligence or reckless disregard by the Advisor of its obligations and
duties hereunder, the Advisor shall not be subject to any liability whatsoever
to the Series, or to any shareholder of the Series, for any error of judgment,
mistake of law or any other act or omission in the course of, or connected with,
rendering services hereunder including, without limitation, for any losses that
may be sustained in connection with the purchase, holding, redemption or sale of
any security on behalf of the Series.
8. Duration and Termination. This Agreement shall become effective on
-------------------------
May 23, 2000 provided that first it is approved by the Board of Trustees of the
Trust,
including a majority of those trustees who are not parties to this Agreement or
interested persons of any party hereto, in the manner provided in Section 15(c)
of the Investment Company Act of 1940, and by the holders of a majority of the
outstanding voting securities of the Series; and shall continue in effect until
May 23, 2002. Thereafter, this Agreement may continue in effect only if such
continuance is approved at least annually by: (i) the Trust's Board of Trustees
or, (ii) by the vote of a majority of the outstanding voting securities of the
Series; and in either event by a vote of a majority of those trustees of the
Trust who are not parties to this Agreement or interested persons of any such
party in the manner provided in Section 15(c) of the Investment Company Act of
1940. This Agreement may be terminated by the Trust at any time, without the
payment of any penalty, by the Board of Trustees of the Trust or by vote of the
holders of a majority of the outstanding voting securities of the Series on 60
days' written notice to the Advisor. This Agreement may be terminated by the
Advisor at any time, without the payment of any penalty, upon 60 days' written
notice to the Trust. This Agreement will automatically terminate in the event of
its assignment. Any notice under this Agreement shall be given in writing,
addressed and delivered or mailed postpaid, to the other party at the principal
office of such party.
As used in this Section 8, the terms "assignment", "interested person", and "a
vote of a majority of the outstanding voting securities" shall have the
respective meanings set forth in Section 2(a)(4), Section 2(a)(19) and Section
2(a)(42) of the 1940 Act and Rule 18f-2 thereunder.
9. Name of Advisor. The parties agree that the Advisor has a proprietary
----------------
interest in the name "Xxxxxxx," and the Trust agrees to promptly take such
action as may be necessary to delete from its corporate name and/or the name of
the Series any reference to the name of the Advisor promptly after receipt from
the Advisor of a written request therefore.
10. Severability. If any provisions of this Agreement shall be held or made
-------------
invalid by a court decision, statute, rule or otherwise, the remainder of this
Agreement shall not be affected thereby.
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
executed as of this 23/rd/ day of May, 2000.
ATTEST: THE XXXXXXX FUNDS:
By: /s/ Xxxxxx X. Xxxxxx By: /s/ Xxxxxx X. Xxxxxxx
---------------------------- -------------------------------
Xxxxxx X. Xxxxxxx
President
ATTEST: XXXXXXX PARTNERS, INC.
By: /s/ Xxxx X. Xxxxx, Xx. By: /s/ Xxxxxxxx X. Xxxxxxxx, Xx.
---------------------------- -------------------------------
Xxxxxxxx X. Xxxxxxxx, Xx.
President and CEO
ATTEST: XXXXXXX PARTNERS, INC.
By: /s/ Xxxx X. Xxxxx, Xx. By: /s/ Xxxx X. Xxxxxx
---------------------------- -------------------------------
Xxxx X. Xxxxxx
Secretary
